Nubeqa

Active substance

Darolutamide

Holder

Bayer SA-NV

Status

closed

Indication

the treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

30/04/2026